Akero Therapeutics Inc. announced new findings from its Phase 2b SYMMETRY and HARMONY trials evaluating efruxifermin in patients with metabolic dysfunction-associated steatohepatitis (MASH), including those with compensated cirrhosis (F4c) and pre-cirrhotic stages (F2-F3). The results, which corroborate previously reported antifibrotic effects and indicate the potential to reduce risk of disease progression in MASH, will be presented at the 76th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025, scheduled for November 7-11, 2025, in Washington, D.C. The data include post-hoc analyses from the 96-week SYMMETRY trial and digital pathology findings from the HARMONY trial, both supporting fibrosis improvements associated with efruxifermin.